Endocrine reviews最新文献_第6页

Retraction and Replacement of: "Effects of Maternal Vitamin D Supplementation on Childhood Health". 撤回和替换：“母亲补充维生素D对儿童健康的影响”。

IF 20.3 1区医学

Endocrine reviews Pub Date : 2025-10-23 DOI: 10.1210/endrev/bnaf031

引用次数: 0

Immune checkpoint inhibitors in high-grade gastroenteropancreatic neuroendocrine neoplasms. 免疫检查点抑制剂在高级别胃肠胰神经内分泌肿瘤中的应用。

IF 20.3 1区医学

Endocrine reviews Pub Date : 2025-10-09 DOI: 10.1210/endrev/bnaf037

Nicola Fazio,Anna La Salvia

{"title":"Immune checkpoint inhibitors in high-grade gastroenteropancreatic neuroendocrine neoplasms.","authors":"Nicola Fazio,Anna La Salvia","doi":"10.1210/endrev/bnaf037","DOIUrl":"https://doi.org/10.1210/endrev/bnaf037","url":null,"abstract":"High-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms (HG-NENs) comprise both highly proliferating well-differentiated NENs, called grade 3 NE tumors, NETs) and poorly differentiated NENs (also named NE carcinomas, NECs). The clinical management of these neoplasms poses unique challenges, and, while platinum plus etoposide is the first-line therapy in advanced setting of NECs, this is not the optimal regimen in G3 NETs in which other chemotherapy schemes, targeted agents and somatostatin analogues have shown to be active. However, overall response rates and clinical benefit are not satisfactory. Interestingly, HG-NENs may be a more suitable target for ICIs than low-grade NENs, because of their higher tumor mutational burden (TMB), increased PD-1 expression, probable increased PD-L1 expression and higher immune infiltration of tumor microenvironment. With these premises, few clinical trials have investigated the efficacy and safety of immune checkpoints inhibitors (ICIs) in HG GEP NENs. With our work we aimed to provide a comprehensive overview of the available literature data about ICIs' role in HG GEPNENs, by analyzing the critical points regarding study population, study design, study results, and potential useful biomarkers for selecting HG-GEP-NENs patients for ICI therapy.","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":"1 1","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity. 基于glp -1的新型2型糖尿病和肥胖症药物。

IF 20.3 1区医学

Endocrine reviews Pub Date : 2025-10-07 DOI: 10.1210/endrev/bnaf036

Jang Won Son,Carel W le Roux,Matthias Blüher,Michael A Nauck,Soo Lim

{"title":"Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity.","authors":"Jang Won Son,Carel W le Roux,Matthias Blüher,Michael A Nauck,Soo Lim","doi":"10.1210/endrev/bnaf036","DOIUrl":"https://doi.org/10.1210/endrev/bnaf036","url":null,"abstract":"The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel GLP-1-based therapeutics are rapidly advancing. These next-generation agents engage not only GLP-1 receptors but also those for other gastro-entero-pancreatic hormones such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, and peptide YY (PYY) to enhance energy uptake, storage, and expenditure through synergistic mechanisms. Both GIP receptor agonism and antagonism, particularly in combination with GLP-1 receptor agonism, have shown promise. Maridebart cafraglutide, combining GLP-1R agonism with GIPR antagonism, exemplifies this innovative approach. Glucagon co-agonists like survodutide and mazdutide have demonstrated significant weight loss and improved glycemic control. Amylin-based agents, including CagriSema (cagrilintide + semaglutide) and amycretin, enhance satiety and glycemic outcomes through complementary actions. Further innovation is seen in triple agonists such as retatrutide, which targets GIP, GLP-1, and glucagon receptors to amplify metabolic effects. Meanwhile, the emergence of orally active small-molecule GLP-1 receptor agonists like danuglipron and orforglipron, which are resistant to enzymatic degradation, marks a major advance in patient-friendly drug delivery. This review explores the mechanisms, clinical development, and therapeutic potential of these novel agents, excluding already approved drugs like liraglutide, semaglutide, and tirzepatide. We highlight how multi-receptor agonists and oral GLP-1-based therapies may reshape the future landscape of obesity and type 2 diabetes treatment by offering more effective and better-tolerated options.","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":"107 1","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145235892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology, Genetic Etiology, and Intervention of Premature Ovarian Insufficiency. 卵巢功能不全的流行病学、遗传病因及干预措施。

IF 22 1区医学

Endocrine reviews Pub Date : 2025-09-16 DOI: 10.1210/endrev/bnaf011

Ting Guo, Hongyuan Liu, Bingying Xu, Yu Qi, Keyan Xu, Xinyi Wu, Xinmiao He, Yingying Qin, Zi-Jiang Chen

{"title":"Epidemiology, Genetic Etiology, and Intervention of Premature Ovarian Insufficiency.","authors":"Ting Guo, Hongyuan Liu, Bingying Xu, Yu Qi, Keyan Xu, Xinyi Wu, Xinmiao He, Yingying Qin, Zi-Jiang Chen","doi":"10.1210/endrev/bnaf011","DOIUrl":"10.1210/endrev/bnaf011","url":null,"abstract":"Premature ovarian insufficiency (POI) is a highly heterogeneous reproductive disorder in both its etiology and clinical presentation. The epidemiological characteristics of POI suggest that its occurrence likely involves a combination of genetic and environmental factors. Deciphering the pathogenic mechanisms of POI is crucial for improving reproductive outcomes as well as managing the long-term complications associated with ovarian dysfunction. Recent studies expand the list of POI causal genes and promote the viability of genetic diagnosis. However, whole exome sequencing studies in large-scale POI cohorts and genome-wide association studies on the age at natural menopause have uncovered a complex genetic architecture underlying POI that includes monogenic and oligogenic inheritance modes, emphasizing the difficulties in genetic diagnosis, especially for the isolated cases. Moreover, our understanding of the physiology of ovarian aging has greatly benefited from recent advances in multiomics analysis, expanding our perspective on the pathogenic mechanisms and potential targeted therapeutic strategies for POI. In this review, we summarize the epidemiological characteristics of POI, as well as progress in genetic and epigenetic etiologies, and discuss advances in pharmacology and material science that will likely contribute to new interventions for ovarian aging. Finally, this review offers new insights into prospects for early diagnosis and treatment of POI, while identifying persistent challenges and potential solutions to be addressed through future research.","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":" ","pages":"621-651"},"PeriodicalIF":22.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stress and Thyroid Function-From Bench to Bedside. 压力和甲状腺功能-从实验室到床边。

IF 22 1区医学

Endocrine reviews Pub Date : 2025-09-16 DOI: 10.1210/endrev/bnaf015

Katja Petrowski, George J Kahaly

{"title":"Stress and Thyroid Function-From Bench to Bedside.","authors":"Katja Petrowski, George J Kahaly","doi":"10.1210/endrev/bnaf015","DOIUrl":"10.1210/endrev/bnaf015","url":null,"abstract":"Experimental animal and human studies illustrate the effect of various stress forms on the thyroid gland and the regulation of thyroid hormones (THs) through the thyrotropic multiloop control circuit. The hypothalamic-pituitary-thyroid axis (HPT) axis is part of the physiological stress system and mediates key regulators of metabolic activity during stress response. Genetically characterized individuals are more affected in their response to stressors, and their psychological response is extremely amplified. This leads to significant increases in TH serum levels as soon as a negative stressor appears. Physical stressors are used to induce psychological stress (eg, physical exercise, starvation, sleep deprivation, hypoxia, and cold temperatures), all of which impact thyroid function. In addition, somatic illnesses may also affect the thyroid gland or may be related to a thyroidal dysfunction. As a psychosocial stressor in animal models, neonatal separation from the mother was used, affecting energy homeostasis and causing an increase in thyroliberin (TRH) expression in female rats and an increase in TRH degrading ectoenzyme in male rats. In mice with restrained stress, THs are important mediators of accelerated tumor growth. In human studies, isolated sexual abuse in childhood doubles the risk of thyroid dysfunction, with puerperal depression after sexual abuse in childhood increasing the risk for HPT axis disorders and elevated thyroid autoantibodies 4-fold. In addition, psychological illnesses influence thyroid function. In the future, laboratory studies with standardized induction of various stress forms are warranted to better understand stress-induced effects on the HPT axis and their corresponding mechanisms.","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":" ","pages":"709-735"},"PeriodicalIF":22.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glycerol and glycerol-3-phosphate: multifaceted metabolites in metabolism, cancer and other diseases. 甘油和甘油-3-磷酸：代谢、癌症和其他疾病中的多方面代谢物。

IF 20.3 1区医学

Endocrine reviews Pub Date : 2025-09-10 DOI: 10.1210/endrev/bnaf033

S R Murthy Madiraju,Elite Possik,Fahd Al-Mulla,Christopher J Nolan,Marc Prentki

{"title":"Glycerol and glycerol-3-phosphate: multifaceted metabolites in metabolism, cancer and other diseases.","authors":"S R Murthy Madiraju,Elite Possik,Fahd Al-Mulla,Christopher J Nolan,Marc Prentki","doi":"10.1210/endrev/bnaf033","DOIUrl":"https://doi.org/10.1210/endrev/bnaf033","url":null,"abstract":"Glycerol and glycerol-3-phosphate are key metabolites at the intersection of carbohydrate, lipid and energy metabolism. Their production and usage are organismal and cell type specific. Glycerol has unique physicochemical properties enabling it to function as an osmolyte, protein structure stabilizer, antimicrobial and antifreeze agent, important to preservation of many biological functions. Glycerol and glycerol-3-phosphate are implicated in many physiological and disease processes relating to energy metabolism, thermoregulation, hydration, skin health, male fertility, aging, and cancer. Glycerol has countless applications in the food, pharmaceutical and cosmetics industries. It is used as a sweetener, preservative, thickening agent, humectant, osmolyte and cryoprotectant. It is widely used in skin and wound care products, laxatives, in cell and tissue preservation and in medicines for numerous conditions. Here, we review the multiple uses and functions of glycerol and glycerol-3-phosphate and associated transporters, enzymes and target genes in health, senescence and disease. We discuss the evidence that glycerol may be present at much higher levels in tissues and cells than in the blood. We bring particular focus to the newly identified glycerol shunt in the direct formation of glycerol independent of lipolysis and as a pathway allowing cells to adapt to various stresses. Relevant to chronic metabolic diseases, cancer and aging, glycerol and glycerol-3-phosphate presents important translational implications and thus warrants much more attention.","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":"24 1","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145025375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: "Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease". 更正：“肠促胰岛素生理学中的葡萄糖依赖性胰岛素多肽：在健康和疾病中的作用”。

IF 20.3 1区医学

Endocrine reviews Pub Date : 2025-08-20 DOI: 10.1210/endrev/bnaf028

引用次数: 0

Correction to: "The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives". 更正：“嗜铬细胞瘤和副神经节瘤的免疫景观：目前的进展和观点”。

IF 20.3 1区医学

Endocrine reviews Pub Date : 2025-08-08 DOI: 10.1210/endrev/bnaf024

引用次数: 0

Correction to: "Imaging of Pheochromocytomas and Paragangliomas". 更正：“嗜铬细胞瘤和副神经节瘤的影像学”。

IF 20.3 1区医学

Endocrine reviews Pub Date : 2025-08-08 DOI: 10.1210/endrev/bnaf023

引用次数: 0

Innovative molecules and delivery technologies enabling the future of GLP-1-based therapies. 创新的分子和传递技术使glp -1为基础的治疗成为可能。

IF 20.3 1区医学

Endocrine reviews Pub Date : 2025-08-04 DOI: 10.1210/endrev/bnaf027

Yining Xu,Daniel J Drucker,Giovanni Traverso,Ana Beloqui

{"title":"Innovative molecules and delivery technologies enabling the future of GLP-1-based therapies.","authors":"Yining Xu,Daniel J Drucker,Giovanni Traverso,Ana Beloqui","doi":"10.1210/endrev/bnaf027","DOIUrl":"https://doi.org/10.1210/endrev/bnaf027","url":null,"abstract":"The multiple physiological effects of gut hormones in different metabolic tissues make them attractive therapeutic targets for the treatment of metabolic diseases. Currently, only GLP-1 receptor-based agonists and oral DPP-4 inhibitors are available on the market. Despite their positive clinical outcomes across a range of indications these treatments present several clinical challenges, including high costs, the need for peptide injections, and requirements for repeated administration. These limitations have driven research into improved GLP-1-based therapies, such as oral small-molecule agonists and novel drug delivery strategies based on emerging GLP-1 medicines. This article describes the challenges in clinical application and development of GLP-1-based pharmacotherapies. We review the development of oral small-molecule agonists and various drug delivery technologies, including ultralong-acting injectable technologies, continuous-acting implantable pumps, smart-acting electronic devices, nutrient-induced cell therapies, and noninvasive delivery systems. We discuss the current state of research, challenges to overcome, and opportunities to improve patient compliance and clinical outcomes. Additionally, we explore how endocrinological effects and patient-oriented needs can guide the development of advanced GLP-1 medicines.","PeriodicalId":11544,"journal":{"name":"Endocrine reviews","volume":"77 6 1","pages":""},"PeriodicalIF":20.3,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0